Corvus Pharmaceuticals (CRVS) Competitors $5.01 +0.28 (+5.92%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRVS vs. KNSA, MRVI, RCUS, OCUL, ARVN, CALT, PRAX, DAWN, ANIP, and AUPHShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Maravai LifeSciences (MRVI), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Arvinas (ARVN), Calliditas Therapeutics AB (publ) (CALT), Praxis Precision Medicines (PRAX), Day One Biopharmaceuticals (DAWN), ANI Pharmaceuticals (ANIP), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Kiniksa Pharmaceuticals Maravai LifeSciences Arcus Biosciences Ocular Therapeutix Arvinas Calliditas Therapeutics AB (publ) Praxis Precision Medicines Day One Biopharmaceuticals ANI Pharmaceuticals Aurinia Pharmaceuticals Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, dividends, media sentiment, risk and earnings. Does the media favor KNSA or CRVS? In the previous week, Kiniksa Pharmaceuticals had 15 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 21 mentions for Kiniksa Pharmaceuticals and 6 mentions for Corvus Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.53 beat Corvus Pharmaceuticals' score of 0.20 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, KNSA or CRVS? Kiniksa Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Is KNSA or CRVS more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals-2.36% -7.31% -5.95% Corvus Pharmaceuticals N/A -70.71%-45.90% Does the MarketBeat Community favor KNSA or CRVS? Corvus Pharmaceuticals received 120 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. However, 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote while only 61.91% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKiniksa PharmaceuticalsOutperform Votes17165.02% Underperform Votes9234.98% Corvus PharmaceuticalsOutperform Votes29161.91% Underperform Votes17938.09% Do analysts recommend KNSA or CRVS? Kiniksa Pharmaceuticals presently has a consensus target price of $36.60, suggesting a potential upside of 97.41%. Corvus Pharmaceuticals has a consensus target price of $12.38, suggesting a potential upside of 147.01%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do institutionals and insiders believe in KNSA or CRVS? 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, KNSA or CRVS? Kiniksa Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals$270.26M4.95$14.08M-$0.14-132.42Corvus PharmaceuticalsN/AN/A-$27.03M-$0.93-5.39 SummaryKiniksa Pharmaceuticals beats Corvus Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$342.49M$6.37B$5.23B$8.96BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-5.399.4187.2917.29Price / SalesN/A310.261,255.8979.02Price / CashN/A61.4443.8235.97Price / Book6.346.055.324.79Net Income-$27.03M$154.90M$122.78M$225.07M7 Day Performance-6.00%-1.72%-0.19%1.51%1 Month Performance6.60%2.69%3.72%4.68%1 Year Performance151.76%2.78%27.31%20.92% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals2.5228 of 5 stars$5.01+5.9%$12.38+147.0%+144.4%$342.49MN/A-5.3930Analyst ForecastShort Interest ↑KNSAKiniksa Pharmaceuticals2.8931 of 5 stars$18.20-8.7%$36.60+101.1%-1.7%$1.31B$384.10M-129.99220Insider TradeAnalyst RevisionNews CoverageGap DownMRVIMaravai LifeSciences4.5776 of 5 stars$5.05+4.1%$10.28+103.6%-23.3%$1.28B$276.92M-3.08610RCUSArcus Biosciences1.891 of 5 stars$13.93-1.9%$34.00+144.1%-17.7%$1.27B$263M-4.42500OCULOcular Therapeutix3.666 of 5 stars$8.10-1.3%$16.71+106.3%+93.0%$1.27B$61.44M-6.14267News CoverageGap DownARVNArvinas2.5729 of 5 stars$18.03-3.2%$63.50+252.2%-50.4%$1.24B$161.10M-3.86420CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180PRAXPraxis Precision Medicines2.0488 of 5 stars$63.66+0.8%$146.33+129.9%+80.8%$1.19B$1.61M-6.18110Short Interest ↑Gap DownDAWNDay One Biopharmaceuticals1.7799 of 5 stars$11.65-1.3%$35.86+207.8%-9.2%$1.17BN/A-11.3160News CoverageHigh Trading VolumeANIPANI Pharmaceuticals4.4768 of 5 stars$53.60-2.6%$77.71+45.0%+5.1%$1.13B$555.46M-97.45600Short Interest ↓AUPHAurinia Pharmaceuticals2.2924 of 5 stars$7.77-3.7%$10.00+28.7%+1.8%$1.11B$220.36M-51.80300Positive News Related Companies and Tools Related Companies Kiniksa Pharmaceuticals Alternatives Maravai LifeSciences Alternatives Arcus Biosciences Alternatives Ocular Therapeutix Alternatives Arvinas Alternatives Calliditas Therapeutics AB (publ) Alternatives Praxis Precision Medicines Alternatives Day One Biopharmaceuticals Alternatives ANI Pharmaceuticals Alternatives Aurinia Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRVS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts